Search Result

Results for "

HCV polymerase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (46) HCV Protease (7) Antibiotic (1) DNA/RNA Synthesis (15) Drug Metabolite (2) Endogenous Metabolite (4) Enterovirus (4) Isotope-Labeled Compounds (3) Nucleoside Antimetabolite/Analog (2) RSV (2) SARS-CoV (9) Topoisomerase (4)
By Research Areas:	Infection (47) Inflammation/Immunology (1)
Click Chemistry:	Azide (3)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Click Chemistry

Targets Recommended: HCV HCV Protease PARP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-101634

ABT-072

HCV Infection

ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

ABT-072	HCV	Infection
ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-109047

Adafosbuvir AL-335	HCV DNA/RNA Synthesis	Infection
Adafosbuvir (AL-335), a precursor compound of a uridine-based nucleotide analog polymerase (NS5B) inhibitor, has potent antiviral activity against *HCV* and acts as a potent inhibitor of HCV RNA polymerase .

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-112047

GSK8175 GSK2878175	HCV	Infection
GSK8175 is a non-nucleoside polymerase (NS5B) inhibitor of hepatitis C virus (HCV). GSK8175 is a sulfonamide- N-benzoxaborole analog with low in vivo clearance across preclinical species and broad-spectrum activity against HCV replicons .

HY-101634A

ABT-072 potassium trihydrate	HCV	Infection
ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-114571

cis-Lomibuvir cis-VX-222	DNA/RNA Synthesis HCV	Infection
cis-Lomibuvir (cis-VX-222) is the cis-isomer of Lomibuvir. Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 *HCV* subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis . cis-Lomibuvir is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14391

PSI-353661 GS-558093	HCV	Infection
PSI-353661 (GS-558093) is a purine nucleotide NS5B polymerase inhibitor against *HCV* infection. PSI-353661 shows EC₉₀s of 8 nM and 11 nM for wild type and S282T resistant replicons of HCV. PSI-353661 can produce high concentrations of the active triphosphate in primary human hepatocytes .

HY-150760

GSK5852 GSK2485852	HCV	Inflammation/Immunology
GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC₅₀ value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC₅₀s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .

HY-13247

Setrobuvir ANA598	DNA/RNA Synthesis HCV SARS-CoV	Infection
Setrobuvir (ANA598) is an orally active non-nucleosidic HCV NS5B polymerase inhibitor. ANA-598 inhibits both de novo RNA synthesis and primer extension, with IC₅₀s between 4 and 5 nM. Setrobuvir also shows excellent binding affinity to SARS-CoV-2 RdRp and induces RdRp inhibition .

HY-10544

Tegobuvir

4 Publications Verification

GS 333126; GS-9190
HCV Infection

Tegobuvir is a specific, covalent inhibitor of the HCV NS5B polymerase.
HY-13465

VCH-916

1 Publications Verification

HCV Infection

VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.
HY-145374

AL-611

HCV Protease Infection

AL-611 is an HCV NS5B polymerase inhibitor (EC₅₀ = 5 nM).

Tegobuvir 4 Publications Verification GS 333126; GS-9190	HCV	Infection
Tegobuvir is a specific, covalent inhibitor of the **HCV NS5B polymerase**.

VCH-916 1 Publications Verification	HCV	Infection
VCH-916 is a novel nonnucleoside HCV NS5B polymerase inhibitor.

AL-611	HCV Protease	Infection
AL-611 is an HCV NS5B polymerase inhibitor (EC₅₀ = 5 nM).

HY-10165

PSI-6130 1 Publications Verification R 1656	HCV	Infection
PSI-6130 is a potent and selective inhibitor of **HCV NS5B polymerase*, and inhibits HCV* replication with a mean IC₅₀ of 0.6 μM.

HY-50680

HCVP-IN-1

HCV Protease Infection

HCVP-IN-1 (compound 1) is a hepatitis C viral polymerase (HCVP) inhibitor .

HCVP-IN-1	HCV Protease	Infection
HCVP-IN-1 (compound 1) is a *hepatitis C viral polymerase* (HCVP)** inhibitor .

HY-15591

TMC647055	HCV	Infection
TMC647055 is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 can be used for the research of Hepatitis C virus (HCV) .

HY-18079

BILB 1941

HCV Infection

BILB 1941 is a potent and specific nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase in vitro .
HY-19558

IDX184

IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC₅₀=0.31 μM, K_i=52.3 nM) .
HY-14775

Nesbuvir

5+ Cited Publications

HCV-796
HCV Infection

Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
HY-12634

Deleobuvir

BI 207127
HCV Infection

Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.

BILB 1941	HCV	Infection
BILB 1941 is a potent and specific nonnucleoside inhibitor of the hepatitis C virus (HCV) RNA polymerase in vitro .

IDX184
IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits **HCV polymerase (IC₅₀=0.31 μM, K_i**=52.3 nM) .

Nesbuvir 5+ Cited Publications HCV-796	HCV	Infection
Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.

Deleobuvir BI 207127	HCV	Infection
Deleobuvir (BI 207127) is a potent non-nucleoside hepatitis C virus (HCV) NS5B polymerase inhibitor.

HY-15591A

TMC647055 Choline salt 1 Publications Verification	HCV	Infection
TMC647055 (Choline salt) is a potent nonnucleoside NS5B polymerase inhibitor of HCV replication. TMC647055 Choline salt has potent HCV combine activity with an IC₅₀ value of 82 nM. TMC647055 Choline salt can be used for the research of Hepatitis C virus (HCV) .

HY-124592

BMT-052

HCV Infection

BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

BMT-052	HCV	Infection
BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-75800

Lomibuvir 2 Publications Verification VX-222	DNA/RNA Synthesis HCV	Infection
Lomibuvir (VX-222), a selective, non-nucleoside polymerase inhibitor, targets thumb pocket 2 of the HCV NS5B polymerase (RdRp) with a K_d of 17 nM. Lomibuvir inhibits the 1b/Con1 *HCV* subgenomic replicon with an EC₅₀ of 5.2 nM. Lomibuvir preferentially inhibits elongative RNA synthesis rather than de novo-initiated RNA synthesis .

HY-12429

Beclabuvir 3 Publications Verification BMS-791325	HCV	Infection
Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC₅₀ of < 28 nM.

HY-15236

PSI-6206 3 Publications Verification RO 2433; GS-331007	HCV	Infection
PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC₉₀ of >100 μM.

HY-19921

JTK-853
JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) *polymerase* inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HY-10240

Mericitabine 5+ Cited Publications RG 7128; R-7128; PSI 6130 diisobutyrate	HCV	Infection
Mericitabine (RG 7128; R-7128) is a nucleoside inhibitor of the **HCV NS5B polymerase** that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication.

HY-10468

NM107 2'-C-Methylcytidine; NM-107	HCV	Infection
NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC₅₀ of NM107 in the wild-type replicon cells is 1.85 μM .

HY-108060

Valopicitabine NM283	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-108060A

Valopicitabine dihydrochloride NM283 dihydrochloride	HCV HCV Protease Nucleoside Antimetabolite/Analog	Infection
Valopicitabine (NM283) dihydrochloride is a nucleoside analog and the orally bioavailable proagent of the potent anti-HCV agent 2'-C-methylcytidine (NM107). NM107competitively inhibits NS5B polymerase, causing chain termination .

HY-15236S

PSI-6206-13C,d3 RO-2433-¹³C,d₃; GS-331007-¹³C,d₃; Sofosbuvir metabolite GS-331007-¹³C,d₃	HCV	Infection
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-10444

R-1479 3 Publications Verification 4'-Azidocytidine	HCV DNA/RNA Synthesis	Infection
R-1479 (4'-Azidocytidine), a nucleoside analogue, is a specific inhibitor of RNA-dependent RNA polymerase (RdRp) of *HCV. R-1479 inhibits HCV* replication in the HCV subgenomic replicon system (IC₅₀=1.28 μM) . R-1479 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-135867

NHC-triphosphate	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-W011834

2'-O-Methylcytidine	HCV	Infection
2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate .

HY-15745A

PSI-7409 tetrasodium 5+ Cited Publications	HCV	Infection
PSI-7409 tetrasodium is an active 5'-triphosphate metabolite of sofosbuvir (PSI-7977), inhibiting **HCV NS5B polymerases, with IC₅₀*s of 1.6, 2.8, 0.7 and 2.6 μM for GT 1b_Con1, GT 2a_JFH1, GT 3a, and GT 4a NS5B polymerases*, respectively.

HY-126303

GS-443902 GS-441524 triphosphate; Remdesivir metabolite	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 (GS-441524 triphosphate) is a potent viral *RNA-dependent RNA-polymerases* (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV** RdRp, respectively. GS-443902 is the active triphosphate metabolite of Remdesivir .

HY-135867A

NHC-triphosphate tetrasodium	Endogenous Metabolite Enterovirus HCV Topoisomerase	Infection
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867E

NHC-triphosphate tetraammonium 5 Publications Verification	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV	Infection
NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-16750

Radalbuvir GS-9669	HCV	Infection
Radalbuvir (GS-9669) is a non-nucleoside inhibitor of nonstructural protein 5B (NS5B) RNA-dependent RNA polymerase (RdRp). Radalbuvir shows strong anti-HCV potency (GT1a intrinsic EC₅₀ = 2.9 nM, GT1b EC₅₀ = 6 nM) .

HY-157291

Antiviral agent 44

Antibiotic HCV Infection

Antiviral agent 44 (compound 7b) is an antiviral agent that has anti-HCV activity in vitro .

Antiviral agent 44	Antibiotic HCV	Infection
Antiviral agent 44 (compound 7b) is an antiviral agent that has anti-HCV activity in vitro .

HY-10241

Simeprevir Maximum Cited Publications 39 Publications Verification TMC435; TMC435350	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) is an oral, potent and highly specific *hepatitis C virus (HCV) NS3/4A protease* inhibitor with a K_i of 0.36 nM. Simeprevir inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-10241A

Simeprevir sodium TMC435 sodium; TMC435350 sodium	HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir (TMC435; TMC435350) sodium is an oral, potent and highly specific *hepatitis C virus (HCV) NS3/4A protease* inhibitor with a K_i of 0.36 nM. Simeprevir sodium inhibits HCV replication with an EC₅₀ of 7.8 nM. Simeprevir sodium also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir sodium inhibits the main protease (M ^pro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses .

HY-19643

JTK-109
JTK-109 is a potent inhibitor of hepatitis C virus NS5B RNA-dependent RNA polymerase. JTK-109 has NS5B inhibitory activity with IC₅₀ value of 0.017μM. JTK-109 can be used for the research of hepatitis C virus (HCV) .

HY-10443

Balapiravir 3 Publications Verification Ro 4588161; R1626	HCV DNA/RNA Synthesis	Infection
Balapiravir (Ro 4588161; R1626) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir has anti-HCV activity . Balapiravir is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-10443A

Balapiravir hydrochloride Ro 4588161 hydrochloride; R1626 hydrochloride	HCV DNA/RNA Synthesis	Infection
Balapiravir hydrochloride (Ro 4588161 hydrochloride; R1626 hydrochloride) is an orally active proagent of a nucleoside analogue inhibitor of the RNA-dependent RNA polymerase (RdRp) of HCV (R1479; 4'-Azidocytidine). Balapiravir hydrochloride has anti-HCV activity . Balapiravir (hydrochloride) is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

HY-15236S1

PSI-6206-d1,13C,15N2 RO 2433--d¹,¹³C,¹⁵N₂; GS-331007--d¹,¹³C,¹⁵N₂	HCV Isotope-Labeled Compounds	Infection
PSI-6206-d1, ¹³C, ¹⁵N₂ is ¹⁵N and ¹³C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC₉₀ of >100 μM.

HY-126303C

GS-443902 trisodium 5+ Cited Publications GS-441524 triphosphate trisodium; Remdesivir metabolite trisodium	DNA/RNA Synthesis SARS-CoV RSV HCV Drug Metabolite	Infection
GS-443902 trisodium (GS-441524 triphosphate trisodium) is a potent viral *RNA-dependent RNA-polymerases* (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV** RdRp, respectively. GS-443902 trisodium is the active triphosphate metabolite of Remdesivir (GS-5734) .

HY-10241S

Simeprevir-13C,d3 TMC435-¹³C,d₃; TMC435350-¹³C,d₃	Isotope-Labeled Compounds HCV HCV Protease SARS-CoV DNA/RNA Synthesis	Infection
Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-W011834S

2'-O-Methylcytidine-d3	Isotope-Labeled Compounds HCV	Infection
2'-O-Methylcytidine-d₃ is deuterium labeled 2'-O-Methylcytidine (HY-W011834). 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-135867F

NHC-diphosphate triammonium 1 Publications Verification	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-diphosphate triammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form . NHC-diphosphate triammonium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867

NHC-triphosphate	Infection Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV
NHC-triphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

HY-135867A

NHC-triphosphate tetrasodium	Structural Classification Natural Products Classification of Application Fields Source classification Other Diseases Endogenous metabolite Disease Research Fields	Endogenous Metabolite Enterovirus HCV Topoisomerase
NHC-triphosphate tetrasodium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form . NHC-triphosphate tetrasodium is a weak alternative substrate for the viral polymerase and can be incorporated into *HCV* replicon RNA .

Cat. No.	Product Name	Chemical Structure

HY-15236S

PSI-6206-13C,d3
PSI-6206- ¹³C,d₃ is the deuterium labeled PSI-6206. PSI-6206 is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC90 of >100 μM.

HY-124592

BMT-052

BMT-052 is a pan-genotypic hepatitis C (HCV) NS5B polymerase primer grip inhibitor .

HY-15236S1

PSI-6206-d1,13C,15N2
PSI-6206-d1, ¹³C, ¹⁵N₂ is ¹⁵N and ¹³C labeled PSI-6206 (HY-15236). PSI-6206 (RO 2433) is the deaminated derivative of PSI-6130, which is a potent and selective inhibitor of HCV NS5B polymerase. PSI-6206 low potently inhibits HCV replicon with EC₉₀ of >100 μM.

HY-10241S

Simeprevir-13C,d3

Simeprevir- ¹³C,d₃ is the ¹³C- and deuterium labeled Simeprevir. Simeprevir is an oral, potent and highly specific hepatitis C virus (HCV) NS3/4A protease inhibitor with a Ki of 0.36 nM. Simeprevir inhibits HCV replication with an EC50 of 7.8 nM. Simeprevir also potently suppresses SARS-CoV-2 replication and synergizes with Remdesivir. Simeprevir inhibits the main protease (Mpro) and the RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2, and also modulates host immune responses[1][2][5].

HY-W011834S

2'-O-Methylcytidine-d3
2'-O-Methylcytidine-d₃ is deuterium labeled 2'-O-Methylcytidine (HY-W011834). 2'-O-Methylcytidine is a 2'-substituted nucleoside as a inhibitor of HCV replication. 2'-O-Methylcytidine inhibits RNA-dependent RNA polymerase (NS5B)-catalyzed RNA synthesis in vitro, in a manner that is competitive with substrate nucleoside triphosphate.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

HCV polymerase

Inhibitors & Agonists

Screening Libraries

NaturalProducts

Isotope-Labeled Compounds

Click Chemistry

Natural
Products